COGT - NASDAQ
Cogent Biosciences, Inc.
$32.26
+0.19%Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live SnapshotCogent Biosciences, Inc. Management Team
Mr. Cole Pinnow
Chief Commercial Officer
Compensation
$443,154
Mr. John L. Green C.A., CPA
Chief Financial Officer & Principal Accounting Officer
Compensation
$729,237
Mr. Evan D. Kearns J.D.
Chief Legal Officer & Corporate Secretary
Dr. Jessica Sachs M.D.
Chief Medical Officer
Compensation
$814,184
Ms. Erin Schellhammer
Chief People Officer
Dr. John Edward Robinson Ph.D.
Chief Scientific Officer
Compensation
$788,901
Mr. Brad Barnett
Chief Technology Officer
Mr. Andrew R. Robbins M.B.A.
President, Chief Executive Officer & Director
Compensation
$1,183,280
Ms. Christi Waarich
Senior Director of Investor Relations
Mr. Dana R. Martin Pharm.D.
Senior Vice President of Medical Affairs & Chief Patient Officer
Cogent Biosciences, Inc. Insider Positioning
During the last 12 months, insiders have purchased $25.00M and sold $382.20M worth of COGT shares, resulting in $357.20M of net selling activity.
3 Months
0
0.00
7.0M
242.62M
-242.6M
-$242.62M
3-6 Months
0
0.00
3.8M
139.58M
-139.6M
-$139.58M
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
2.8M
25.00M
0
0.00
+25.0M
+$25.00M
Top Buyers
Fairmount Funds Management Llc
Director
$25.00M
Top Sellers
Fairmount Funds Management Llc
Director
$370.02M
Robinson John Edward
Officer: Chief Scientific Officer
$3.49M
Sachs Jessica
Officer: Chief Medical Officer
$3.20M
Green John L.
Officer: Chief Financial Officer
$2.98M
Kearns Evan
Officer: Chief Legal Officer
$2.52M
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $357.20M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
COGT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 23, 2026 | June 09, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 22, 2025 | June 04, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 23, 2024 | June 05, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 25, 2023 | June 07, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 26, 2022 | June 07, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 30, 2021 | June 16, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 29, 2020 | June 09, 2020 | 2020 | |
DEF 14A DEF 14A 2020 N/A | February 18, 2020 | March 09, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 30, 2019 | June 18, 2019 | 2019 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.